Many of the life science companies I talk to don't have a marketing problem. They have a sequencing problem. They're running a trade show booth, a LinkedIn ad campaign, and a half-finished website refresh all at once, and nobody can say which of those things is supposed to move a deal forward. A good life science marketing strategy fixes that by deciding what matters at your current stage and ignoring the rest, at least for now.

I've spent 25+ years in marketing, working with everyone from early-stage startups to Fortune 500 brands, and the pattern in technical, regulated categories is consistent: the science is rarely the bottleneck. The bottleneck is translating that science into a commercial story that the person signing the purchase order actually cares about. This guide is written for Texas founders and commercial leaders in biotech, diagnostics, lab tools, and research services who want a plain answer to three questions: what should we do first, what will it cost, and who should own it.

Why Life Science Marketing Is Its Own Discipline

You've probably read the standard list: long sales cycles, technical buyers, regulatory constraints, multiple stakeholders. All true. But the part that trips up many teams is simpler. In life sciences, the person who reads your data is often not the person who approves the spend.

The bench scientist or principal investigator evaluates whether your assay, instrument, or platform works. The lab manager worries about workflow and supply. Procurement and finance care about cost and vendor risk. In clinical settings, add compliance and sometimes payers. Each of those people needs a different reason to say yes, and a strategy that only speaks to the scientist tends to stall at the final approval stage.

Add regulatory review on claims, sales cycles that can stretch past a year, and an audience that is trained to be skeptical of marketing language, and you get a category where generic B2B playbooks underperform. Not because they're wrong, but because they skip the evidence and the stakeholder mapping that this audience requires.

Start With Your Stage, Not Your Channels

The most useful thing I can tell a life science leadership team is this: your strategy should look very different depending on where the company is. Here's how I typically break it down.

Stage 1: Pre-commercial or platform stage

You have promising data, maybe grant funding or a seed round, and no product revenue yet. Marketing here is mostly about credibility and narrative. The audiences that matter are investors, potential partners, key opinion leaders, and future hires. Priorities typically include a clear positioning statement that a non-scientist can repeat, a website that explains the problem and the approach without overclaiming, a publication and conference plan tied to your data readouts, and a disciplined founder presence on LinkedIn. What you usually don't need yet is paid demand generation. There's nothing to convert people into.

Stage 2: First commercial product

In my experience, this is where a lot of marketing money gets wasted. You have something to sell, a small sales team (often one or two people), and a lot of pressure to show pipeline. The strategy work here is about focus: picking the two or three customer segments where your evidence is strongest, building the sales enablement materials your reps actually need (application notes, comparison data, an ROI story for the economic buyer), and choosing a small number of channels you can do well. For many lab-tools and diagnostics companies, that means a targeted account list, a short email nurture built around technical content, and two or three conferences where your buyers actually show up, not ten where they might.

Stage 3: Scaling a commercial portfolio

Now you have multiple products or segments, a real sales organization, and enough data to see what's working. Strategy shifts toward systems: account-based programs for priority institutions, a content engine that compounds in search, marketing operations and attribution that hold up across long cycles, and a team structure that can sustain it. This is also the stage where under-investing in marketing leadership starts to cost real money, because the decisions get bigger and the mistakes get more expensive.

The Five Decisions That Make Up a Real Strategy

Whatever your stage, a life science marketing strategy comes down to five decisions. If you can write each one down in a sentence or two, you have a strategy. If you can't, you have a list of activities.

1. Who exactly are we selling to? Not "pharma and academia." Something closer to "translational research labs at academic medical centers running this specific workflow, plus the core facility managers who buy for them." Specificity drives everything downstream.
2. What is our claim, and what evidence backs it? Scientists will check. Your positioning should be built from the strongest defensible claim you have, with the data ready to show. If marketing and regulatory or scientific affairs aren't aligned on that claim, fix that before you spend a dollar on promotion.
3. Which stakeholders need which message? Map the buying group. Write down what the scientist, the lab manager, the finance approver, and (where relevant) the clinician each need to believe. Then make sure you have at least one asset for each.
4. Which few channels will we do well? Conferences, scientific content, email, search, LinkedIn, webinars with credible speakers, direct outreach. All of these can work. Doing all of them at once with a small team usually doesn't.
5. How will we measure progress over a long cycle? If your sales cycle runs nine to eighteen months, last-click lead counts will mislead you. Track engagement within target accounts, pipeline influenced, and stage-to-stage movement. Agree on those measures with sales up front.

The Texas Angle

Texas has a real and growing life science ecosystem: the Texas Medical Center in Houston, UT Southwestern and a cluster of research and device companies in Dallas-Fort Worth, a growing biotech community in Austin, and San Antonio's long-standing biomedical research base. That creates a few advantages Texas companies don't always use.

First, proximity to major research and clinical institutions means you can often get early pilots, reference sites, and KOL relationships closer to home than coastal companies assume. A credible local reference customer can be worth more than a national ad budget at the first-product stage.

Second, the talent picture is different. In my experience, senior marketers with deep life science backgrounds are harder to find locally than in the older coastal hubs, which can make the first senior marketing hire slow and expensive here. That's one reason some Texas companies end up stitching together contractors without anyone owning the overall strategy.

Third, many of the Texas life science founders I meet came out of academia or large healthcare organizations. They know the science and the customer deeply. What they usually want from marketing is someone who can turn that knowledge into a repeatable commercial system without diluting the credibility they've earned.

What It Costs and Who Should Own It

There are three common ways to staff life science marketing strategy, and each one fits a different situation.

A full-time marketing leader. Right when you're at the scaling stage, have budget to support a team, and need someone fully embedded in commercial planning every day. In my experience, a senior hire with life science background is a significant commitment once you add salary, benefits, equity, and the time it takes to recruit. If you need that person and can afford them, hire them.

A specialized agency. Useful for execution: content, design, campaigns, events. A good one will understand scientific audiences. The gap is that agencies are typically built to deliver the scope you hand them, not to decide what the scope should be. Someone on your side still has to own the strategy.

A fractional CMO. This is the model we run at TexasCMO, and it fits best at the first-product stage and the early scaling stage, when you need senior strategic leadership but not forty hours a week of it. What makes our approach different is that we're agency-backed, so the strategy comes with an execution bench rather than a slide deck you then have to staff. You can see how that works in our turn-key marketing option, or if you'd rather build internal capability, in how we help you build your marketing team. Our pricing page lays out what engagements cost, because I think buyers deserve to see that before a sales call.

Now the honest part. Fractional is the wrong answer in some life science situations. If you're a pharma company preparing a major product launch with a large field force and formal medical-legal-regulatory review on every asset, you likely need a full-time commercial leader and an established compliance process. If your board expects a marketing executive in every operating meeting and on every investor call, that's a full-time job. And if you haven't yet confirmed there's a market for the product, no marketing leader of any kind will fix that. Spend the money on customer discovery first.

Red Flags When You're Vetting Help

Whether you're hiring a person, an agency, or a fractional leader, watch for these:

• Channel-first recommendations. If the first conversation is about which ads to run before anyone has asked about your evidence, your buyers, or your sales cycle, keep looking.
• Comfort with overclaiming. Anyone who encourages you to stretch what your data supports is creating regulatory and reputational risk, and sophisticated buyers will notice.
• No plan for sales alignment. In long-cycle B2B, marketing that isn't tied to how your reps sell tends to produce activity without pipeline.
• Vague pricing and vague deliverables. You should know what you're paying for and what you'll have at 30, 60, and 90 days.
• Short-cycle metrics on a long-cycle business. Promises of fast lead volume usually mean the wrong leads.

If you want to see the kind of background I bring to that conversation, my experience page covers it.

Frequently Asked Questions

What is a life science marketing strategy?

It's a plan that defines which customers you're targeting, what evidence-backed claim you're making, which stakeholders in the buying group need which message, which channels you'll invest in, and how you'll measure progress over a long sales cycle. The tactics come after those decisions, not before.

How is marketing to scientists different from other B2B marketing?

Scientists expect data, precision, and honesty about limitations. Buzzwords and broad claims tend to hurt credibility rather than help it. Content that teaches, such as application notes, method comparisons, and webinars with credible presenters, typically outperforms promotional messaging with this audience.

How much should a life science company spend on marketing?

It depends heavily on stage. Pre-commercial companies usually spend modestly and focus on narrative and credibility. Companies with a first product typically need enough budget for focused enablement, a few well-chosen channels, and senior strategic leadership. I'd rather see a small budget spent with discipline than a large one spread across every channel at once.

When does a fractional CMO make sense for a life science company?

Usually when you have a product to sell or are close to it, need senior strategic direction, and don't yet need or can't yet justify a full-time executive. It's less suited to large pharma launches with heavy compliance infrastructure, or to companies that haven't validated their market yet.

Where to Start

If you're a Texas life science company and your marketing feels like a collection of activities rather than a plan, start by writing down the five decisions above and being honest about your stage. If you'd like a second set of eyes on that, we'll take a look at where you are, what's working, and what we'd change first. Book an audit and we'll give you a straight answer, including if we're not the right fit.